Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

rediff.com -  Anjali Singh - Piramal Pharma looks to return on growth path
Piramal Pharma looks to return on growth path
Rediff.com

Piramal Pharma is strategically positioning itself for a robust financial year 2026-27, projecting significant revenue expansion and a sharp rebound in profitability after navigating a challenging period of macro headwinds and inventory destocking.

chron.com - BridgeBio Pharma: Q1 Earnings Snapshot
BridgeBio Pharma: Q1 Earnings Snapshot
Chron

PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $164 million in its first quarter. The Palo Alto, California-based company said it had a loss of 84 cents per share. The…

seekingalpha.com - SA Transcript Insights Editor - GoodRx raises 2026 outlook to $765M-$785M revenue and at least $235M adjusted EBITDA, led by Pharma Direct (NASDAQ:GDRX)
GoodRx raises 2026 outlook to $765M-$785M revenue and at least $235M adjusted EBITDA, led by Pharma Direct (NASDAQ:GDRX)
Seeking Alpha

Strong Pharma Direct performance, higher subscription growth, and resilient platform engagement are driving the upward revision in revenue and EBITDA guidance, despite continued pressure on legacy prescription transactions revenue. Pharma Direct is…

pymnts.com - PYMNTS - Big Pharma Runs Its Checkout Counter Through GoodRx
Big Pharma Runs Its Checkout Counter Through GoodRx
PYMNTS.com | Breaking News, Trends and Analysis

Pharma Direct, the unit that connects pharmaceutical manufacturers directly to consumers through point-of-sale pricing programs, grew 82% year over year in Q1. The platform now runs more than 125 self-pay programs. GoodRx handled approximately one…

marketbeat.com - NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
MarketBeat

NewAmsterdam Pharma NASDAQ: NAMS said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what executives described as encouraging trends in…

globenewswire.com - Nxera Pharma - Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
GlobeNewswire

Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”)…

marketbeat.com - Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00
MarketBeat

Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its target price boosted by analysts at Citigroup from $50.00 to $66.00 in a report issued on Thursday, Benzinga reports. The firm currently has a 'buy' rating on the biopharmaceutical company's…

marketbeat.com - Ascendis Pharma A/S Q1 Earnings Call Highlights
Ascendis Pharma A/S Q1 Earnings Call Highlights
MarketBeat

Can BioMarin Stock Live Up to Wall Street's High Expectations? Ascendis Pharma A/S NASDAQ: ASND reported first-quarter 2026 results highlighted by the U.S. FDA approval of its third TransCon product, YUVIWEL, and continued growth across its rare…

marketbeat.com - JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price
MarketBeat

Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its price objective increased by equities researchers at JPMorgan Chase & Co. from $50.00 to $58.00 in a report released on Thursday, Benzinga reports. The firm currently has an 'overweight' rating…

marketbeat.com - Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up After Strong Earnings
Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up After Strong Earnings
MarketBeat

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $45.30, but opened at $55.36. Zealand Pharma…

wsj.com - AdriĆ  Calatayud - Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown
Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown
Wall Street Journal

The chief executive of generic-drug maker Group expects the market for unbranded versions of popular weight-loss medicines to be big. Just how big, though, he doesn't dare to forecast. “I've been in generics for 35 years and I've never known…

newsweek.com - Alexis Kayser - Inside the fast-tracked FDA
Inside the fast-tracked FDA
Newsweek

This is a preview of the May 1 edition of Access Health— Tap here to get this newsletter delivered straight to your inbox on Thursday mornings. Good morning. This week, I attended the launch event for the West Health Accelerator at the…

news-medical.net - Bruker unveils new NMR products and workflow solutions at ENC 2026
Bruker unveils new NMR products and workflow solutions at ENC 2026
News-Medical

At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation today announced new NMR products and workflow solutions designed to expand performance, sensitivity, and automation across research and applied NMR. The…

seekingalpha.com - John Vincent - Tracking Tweedy Browne Portfolio - Q1 2026 Update (NYSEARCA:COPY)
Tracking Tweedy Browne Portfolio - Q1 2026 Update (NYSEARCA:COPY)
Seeking Alpha

Tweedy Browne's Q1 2026 13F portfolio rose to ~$1.26B with 93 holdings, led by CNH Industrial (17.61%). Significant portfolio concentration: top five positions (CNH, Ionis Pharma, Berkshire Hathaway, Coca-Cola FEMSA, and Alphabet) comprise ~57%.

bloomberg.com - Sackler Family Member Admits Felony Tied to Her Opioid Addiction
Sackler Family Member Admits Felony Tied to Her Opioid Addiction
Bloomberg

As the Sackler family worked through a plan to pay $6.5 billion to resolve their liability over Purdue Pharma LP 's production of addictive opioids, the epidemic hit even closer to home. Joss Sackler, the wife of former Purdue board member David…

Receive a Daily briefing on Pharma Industry News

Get Started